![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Fujifilm Begins Late-Stage Trial of Avigan for COVID-19
Fujifilm Begins Late-Stage Trial of Avigan for COVID-19
![Fujifilm_Logo.gif](https://www.fdanews.com/ext/resources/test/Device_Images5/Fujifilm_Logo.gif?t=1590463315&width=430)
Fujifilm has launched a phase 3 trial in Japan to evaluate its antiviral drug Avigan (favipiravir) as a potential treatment for COVID-19 patients. Avigan is currently approved in Japan as an influenza treatment.
In December 2020, Japan’s health ministry said trial data used to support the drug’s submission as a COVID-19 antiviral were inconclusive. The new study will specifically target patients 50 years and older as well as high-risk patients.
Avigan has already been approved as a COVID-19 antiviral in Russia, India and Indonesia.
Upcoming Events
-
18Jul
-
21Oct